The effect of a DNA repair gene on cellular invasiveness: Xrcc3 over-expression in breast cancer cells

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Martinez Marignac, Veronica L ^a   Rodrigue, Amélie ^d   Davidson, David ^a   Couillard, Martin ^a   Al Moustafa, Ala Eddin ^a   Abramovitz, Mark ^a   Foulkes, William D ^b   Masson, Jean Yves ^d   Aloyz, Raquel ^a,b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DISCOIDIN DOMAIN RECEPTOR 1; GELATINASE B; HERMES ANTIGEN; INHIBITOR OF DIFFERENTIATION 1; KU ANTIGEN; KU80 ANTIGEN; RAD51 PROTEIN; TRANSCRIPTION FACTOR SP2; TREFOIL FACTOR 1; UNCLASSIFIED DRUG; XRCC3 PROTEIN; DNA BINDING PROTEIN; TUMOR PROTEIN; X-RAY REPAIR CROSS COMPLEMENTING PROTEIN 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST METASTASIS; CANCER CELL; CELL ADHESION; CELL INVASION; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA REPAIR; FEMALE; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHENOTYPIC VARIATION; BREAST TUMOR; CANCER INVASION; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; UPREGULATION;

BREAST NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; DNA REPAIR; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; UP-REGULATION;

EID: 79551568711     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016394     Document Type: Article

References (48)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al. (2007) Cancer statistics, 2007. CA Cancer J Clin 57: 43-66.
2. Canadian Cancer Statistics 2010. Toronto: Canadian Cancer Society's Steering Committee).
3. Mimeault M, Batra SK (2010) New promising drug targets in cancer- and metastasis-initiating cells. Drug Discov Today 15: 354-364.
4. Aloyz R, Xu ZY, Bello V, Bergeron J, Han FY, et al. (2002) Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD. Cancer Res 62: 5457-5462.
5. Liu C, Zhou S, Begum S, Sidransky D, Westra WH, et al. (2007) Increased expression and activity of repair genes TDP1 and XPF in non-small cell lung cancer. Lung Cancer 55: 303-311.
6. Lord RV, Brabender J, Gandara D, Alberola V, Camps C, et al. (2002) Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8: 2286-2291.
7. Xu ZY, Loignon M, Han FY, Panasci L, Aloyz R (2005) Xrcc3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis. J Pharmacol Exp Ther 314: 495-505.
8. Ganguly A, Shields CL (2010) Differential gene expression profile of retinoblastoma compared to normal retina. Mol Vis 16: 1292-1303.
9. Kauffmann A, Rosselli F, Lazar V, Winnepenninckx V, Mansuet-Lupo A, et al. (2008) High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene 27: 565-573.
10. O'Donnell RK, Kupferman M, Wei SJ, Singhal S, Weber R, et al. (2005) Gene expression signature predicts lymphatic metastasis in squamous cell carcinoma of the oral cavity. Oncogene 24: 1244-1251.
11. Sarasin A, Dessen P (2010) DNA repair pathways and human metastatic malignant melanoma. Curr Mol Med 10: 413-418.
12. Sarasin A, Kauffmann A (2008) Overexpression of DNA repair genes is associated with metastasis: a new hypothesis. Mutat Res 659: 49-55.
13. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, et al. (2002) A geneexpression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009.
14. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, et al. (2005) Geneexpression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365: 671-679.
15. Harris AL (1985) DNA repair: relationship to drug and radiation resistance, metastasis and growth factors. Int J Radiat Biol Relat Stud Phys Chem Med 48: 675-690.
16. Monferran S, Paupert J, Dauvillier S, Salles B, Muller C (2004) The membrane form of the DNA repair protein Ku interacts at the cell surface with metalloproteinase 9. EMBO J 23: 3758-3768.
17. Paupert J, Dauvillier S, Salles B, Muller C (2007) Transport of the leaderless protein Ku on the cell surface of activated monocytes regulates their migratory abilities. EMBO Rep 8: 583-588.
18. Kessenbrock K, Plaks V, Werb Z () Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141: 52-67.
19. Bourguignon LY, Gunja-Smith Z, Iida N, Zhu HB, Young LJ, et al. (1998) CD44v(3,8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. J Cell Physiol 176: 206-215.
20. Yu Q, Stamenkovic I (2000) Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14: 163-176.
21. Loignon M, Amrein L, Dunn M, Aloyz R (2007) XRCC3 depletion induces spontaneous DNA breaks and p53-dependent cell death. Cell Cycle 6: 606-611.
22. Pierce AJ, Johnson RD, Thompson LH, Jasin M (1999) XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev 13: 2633-2638.
23. Bishop DK, Ear U, Bhattacharyya A, Calderone C, Beckett M, et al. (1998) Xrcc3 is required for assembly of Rad51 complexes in vivo. J Biol Chem 273: 21482-21488.
24. Hussain S, Wilson JB, Blom E, Thompson LH, Sung P, et al. (2006) Tetratricopeptide-motif-mediated interaction of FANCG with recombination proteins XRCC3 and BRCA2. DNA Repair (Amst) 5: 629-640.
25. Wilson JB, Yamamoto K, Marriott AS, Hussain S, Sung P, et al. (2008) FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3. Oncogene 27: 3641-3652.
26. Wang ZM, Chen ZP, Xu ZY, Christodoulopoulos G, Bello V, et al. (2001) In vitro evidence for homologous recombinational repair in resistance to melphalan. J Natl Cancer Inst 93: 1473-1478.
27. Xu Z, Chen ZP, Malapetsa A, Alaoui-Jamali M, Bergeron J, et al. (2002) DNA repair protein levels vis-a-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program. Anticancer Drugs 13: 511-519.
28. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
29. Azzam HS, Arand G, Lippman ME, Thompson EW (1993) Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production. J Natl Cancer Inst 85: 1758-1764.
30. Yoshida K, Bolodeoku J, Sugino T, Goodison S, Matsumura Y, et al. (1995) Abnormal retention of intron 9 in CD44 gene transcripts in human gastrointestinal tumors. Cancer Res 55: 4273-4277.
31. Tomayko MM, Reynolds CP (1989) Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24: 148-154.
32. Fong S, Itahana Y, Sumida T, Singh J, Coppe JP, et al. (2003) Id-1 as a molecular target in therapy for breast cancer cell invasion and metastasis. Proc Natl Acad Sci U S A 100: 13543-13548.
33. Muller C, Paupert J, Monferran S, Salles B (2005) The double life of the Ku protein: facing the DNA breaks and the extracellular environment. Cell Cycle 4: 438-441.
34. Sumida T, Itahana Y, Hamakawa H, Desprez PY (2004) Reduction of human metastatic breast cancer cell aggressiveness on introduction of either form a or B of the progesterone receptor and then treatment with progestins. Cancer Res 64: 7886-7892.
35. Hou G, Vogel WF, Bendeck MP (2002) Tyrosine kinase activity of discoidin domain receptor 1 is necessary for smooth muscle cell migration and matrix metalloproteinase expression. Circ Res 90: 1147-1149.
36. Ling MT, Wang X, Zhang X, Wong YC (2006) The multiple roles of Id-1 in cancer progression. Differentiation 74: 481-487.
37. Nieborowska-Skorska M, Hoser G, Rink L, Malecki M, Kossev P, et al. (2006) Id1 transcription inhibitor-matrix metalloproteinase 9 axis enhances invasiveness of the breakpoint cluster region/abelson tyrosine kinase-transformed leukemia cells. Cancer Res 66: 4108-4116.
38. Park HS, Kim KR, Lee HJ, Choi HN, Kim DK, et al. (2007) Overexpression of discoidin domain receptor 1 increases the migration and invasion of hepatocellular carcinoma cells in association with matrix metalloproteinase. Oncol Rep 18: 1435-1441.
39. Shimada K, Nakamura M, Ishida E, Higuchi T, Yamamoto H, et al. (2008) Prostate cancer antigen-1 contributes to cell survival and invasion though discoidin receptor 1 in human prostate cancer. Cancer Sci 99: 39-45.
40. Amiry N, Kong X, Muniraj N, Kannan N, Grandison PM, et al. (2009) Trefoil factor-1 (TFF1) enhances oncogenicity of mammary carcinoma cells. Endocrinology 150: 4473-4483.
41. Crosier M, Scott D, Wilson RG, Griffiths CD, May FE, et al. (2001) High expression of the trefoil protein TFF1 in interval breast cancers. Am J Pathol 159: 215-221.
42. Perry JK, Kannan N, Grandison PM, Mitchell MD, Lobie PE (2008) Are trefoil factors oncogenic? Trends Endocrinol Metab 19: 74-81.
43. Prest SJ, May FE, Westley BR (2002) The estrogen-regulated protein, TFF1, stimulates migration of human breast cancer cells. FASEB J 16: 592-594.
44. Kubota T, Yamaguchi H, Watanabe M, Yamamoto T, Takahara T, et al. (1993) Growth of human tumor xenografts in nude mice and mice with severe combined immunodeficiency (SCID). Surg Today 23: 375-377.
45. Zhai YF, Esselman WJ, Oakley CS, Chang CC, Welsch CW (1992) Growth of MCF-7 human breast carcinoma in severe combined immunodeficient mice: growth suppression by recombinant interleukin-2 treatment and role of lymphokine-activated killer cells. Cancer Immunol Immunother 35: 237-245.
46. Honrado E, Osorio A, Palacios J, Milne RL, Sanchez L, et al. (2005) Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors. J Clin Oncol 23: 7503-7511.
47. Kelman Z (1997) PCNA: structure, functions and interactions. Oncogene 14: 629-640.
48. Theunissen PH, Leers MP, Bollen EC (1992) Proliferating cell nuclear antigen (PCNA) expression in formalin-fixed tissue of non-small cell lung carcinoma. Histopathology 20: 251-255.